Download: Quick Fact Sheet
Second Quarterly Call Earnings Call Transcript
TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.
Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.
TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.
Dr. Glynn Wilson, Chairman and CEO
TapImmune Inc. is a leader in the immunotherapy of women’s cancers. The Company is advancing its two clinical-stage T-cell vaccine candidates in multiple Phase 2 and Phase 1b/2 clinical trials that address the unmet need in ovarian and breast cancer...
Get our news delivered to your inbox
Join the TPIV VIP List